Reference : HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative...
Scientific journals : Article
Human health sciences : Surgery
Human health sciences : Immunology & infectious disease
Human health sciences : Hematology
http://hdl.handle.net/2268/102048
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia
English
Baron, Frédéric mailto [Université de Liège - ULg > Département des sciences cliniques > Hématologie]
Maris, M. B. [> > > >]
Storer, B. E. [> > > >]
Sandmaier, B. M. [> > > >]
Stuart, M. J. [> > > >]
McSweeney, P. A. [> > > >]
Radich, J. P. [> > > >]
Pulsipbek, M. A. [> > > >]
Agura, E. D. [> > > >]
Chauncey, T. R. [> > > >]
Maloney, D. G. [> > > >]
Shizuru, J. A. [> > > >]
Storb, R. [> > > >]
Apr-2005
Biology of Blood and Marrow Transplantation
Carden Jennings Publ Co Ltd
11
4
272-279
Yes (verified by ORBi)
International
1083-8791
Charlottesville
[en] chronic myeloid leukemia ; hematopoietic cell transplantation ; unrelated donor ; non-myeloblative ; chimerism ; graft rejection
[en] We evaluated 10/10 HLA antigen-matched unrelated hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning with fludarabine 3 x 30 mg/m(2) and 2 Gy of total body irradiation as treatment for patients with chronic myeloid leukemia who were ineligible for conventional HCT. Data from 21 consecutive patients in first chronic phase (CP1; n = 12), accelerated phase (AP; n = 5), second CP (CP2; n = 3), and blast crisis (n = 1) were analyzed. Stem cell sources were bone marrow (n = 4) or granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells (G-PBMCs; n = 17). The patient who underwent transplantation in blast crisis died on day 21 (too early to be evaluated. for engraftment) from progressive disease. Sustained engraftment was achieved in 5 of 12 patients who underwent transplantation in CP1, 4 of 5 patients who underwent transplantation in AP, and 2 of 3 patients who underwent transplantation in CP2, whereas 9 patients rejected their grafts between 28 and 400 days after HCT. Specifically, I of 4 marrow recipients and 10 of 17 G-PBMC recipients achieved sustained engraftment. Graft rejections were nonfatal in all cases and were followed by autologous reconstitution with persistence or recurrence of chronic myeloid leukemia. Seven of 11 patients with sustained engraftment-including all 5 patients in CP 1, 2 of 4 patients in AP, and neither of the 2 patients in CP2-were alive in complete cytogenetic remissions 118 to 1205 days (median, 867 days) after HCT. Two of the remaining 4 patients died of nonrelapse causes in complete (n = 1) or major (n = 1) cytogenetic remissions, and 2 died of progressive disease. Further efforts are directed at reducing the risk of graft rejection by exclusive use of G-PBMC and increasing the degree of pretransplantation immunosuppression. (c) 2005 American Society for Blood and Marrow Transplantation.
http://hdl.handle.net/2268/102048

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
BaronCMLBBMT05.pdfPublisher postprint152.8 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.